摘要
目的探讨奥美拉唑和艾司奥美拉唑治疗急性非静脉曲张性消化道出血(ANVUGIB)的成本-效果。方法采用成本-效果分析。效果指标为治疗ANVUGIB的有效率。直接医疗成本中包括药品价格。以增量成本效果比(ICER)作为决策指标,对效果及药品价格进行单因素敏感性分析,采用蒙特卡洛模拟对参数随机抽样进行概率敏感性分析。结果成本-效果基础分析显示艾司奥美拉唑与奥美拉唑比较的ICER值为896.2元,敏感性分析结果与基础分析结果一致,概率敏感性分析结果显示当支付意愿(WTP)为800元以上,艾司奥美拉唑是更经济的方案。单因素敏感性分析显示,在影响ICER的各因素中,艾司奥美拉唑的价格为最敏感因素。结论每治疗一例有效的ANVUGIB患者的WTP值在800元或以上时,艾司奥美拉唑具有经济学优势。
Objective To evaluate the economic efficiency of omeprazole and esomeprazole in the treatment of acute non-varicose gastrointestinal bleeding. Methods Cost-effectiveness analysis was used. The outcome index was the effective rate of ANVUGIB treatment. Direct medical costs included drug prices. Incremental cost-effectiveness Ratio(ICER) was used as a decision indicator to conduct a single-factor sensitivity analysis of effectiveness and drug price, and monte carlo simulation was used to conduct a probabilistic sensitivity analysis of random sampling of parameters. Results The cost-effect basis analysis showed that the ICER of omeprazole and esomeprazole and was $ 896.2. Single factor sensitivity analysis showed that the sensitivity analysis results were consistent with the basic analysis results, and the probability sensitivity analysis showed that esomeprazole was a more economical solution when the WTP was above $800. Among the factors affecting ICER, the price of esomeprazole is the most sensitive factor. Conclusion When the WTP value of an effective ANVUGIB patient is 800 yuan or more, omeprazole has economic advantages.
作者
石丰豪
SHI Feng-Hao(China Pharmaceutical University,Nanjing 211198,China)
出处
《中国药物经济学》
2020年第6期31-34,共4页
China Journal of Pharmaceutical Economics
